• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by TriSalus Life Sciences Inc.

    5/15/26 4:44:22 PM ET
    $TLSI
    Medical Specialities
    Health Care
    Get the next $TLSI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    TriSalus Life Sciences, Inc.

    (Name of Issuer)


    Common Stock, $0.01 par value

    (Title of Class of Securities)




    89680M101

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    89680M101


    1Names of Reporting Persons

    First Light Asset Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,374,117.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,374,117.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,374,117.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.75 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP Number(s):
    89680M101


    1Names of Reporting Persons

    Mathew P. Arens
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,374,117.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,374,117.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,374,117.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.75 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TriSalus Life Sciences, Inc.
    (b)Address of issuer's principal executive offices:

    6272 W. 91st Ave., Westminster, CO 80031
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is jointly filed by the following: First Light Asset Management, LLC (the "Manager") Mathew P. Arens ("Mr. Arens") The Manager may be deemed to be the beneficial owner of 5,374,117 of the Issuer's shares of common stock (the "Shares"). The Manager acts as an investment adviser to certain persons holding separately managed accounts with the Manager, each of whom has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, those shares. The Manager may also be deemed to be the beneficial owner of these shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls the Manager in his position as managing member and majority owner of the Manager. The Manager and Mr. Arens are filing this Schedule 13G/A with respect to these Shares pursuant to Rule 13d-1(b) under the Act. The Manager and Mr. Arens may be deemed to be the beneficial owner of the total amount of Shares set forth across from its or his respective name in Item 4 below. The filing of this Schedule 13G shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934.
    (b)Address or principal business office or, if none, residence:

    Each of the reporting persons identified in Item 2(a) has its principal business office at: 3300 Edinborough Way, Suite 201, Edina, MN 55435
    (c)Citizenship:

    First Light Asset Management, LLC - Delaware limited liability company Mathew P. Arens - United States citizen
    (d)Title of class of securities:

    Common Stock, $0.01 par value
    (e)CUSIP Number(s):

    89680M101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    First Light Asset Management, LLC - 5,374,117 Mathew P. Arens - 5,374,117
    (b)Percent of class:

    First Light Asset Management, LLC - 8.75% Mathew P. Arens - 8.75%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    First Light Asset Management, LLC - 0 Mathew P. Arens - 0

     (ii) Shared power to vote or to direct the vote:

    First Light Asset Management, LLC - 5,374,117 Mathew P. Arens - 5,374,117

     (iii) Sole power to dispose or to direct the disposition of:

    First Light Asset Management, LLC - 0 Mathew P. Arens - 0

     (iv) Shared power to dispose or to direct the disposition of:

    First Light Asset Management, LLC - 5,374,117 Mathew P. Arens - 5,374,117

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    First Light Asset Management, LLC
     
    Signature:/s/ Kurt T. Peterson
    Name/Title:Kurt T. Peterson/Chief Compliance Officer
    Date:05/15/2026
     
    Mathew P. Arens
     
    Signature:/s/ Mathew P. Arens
    Name/Title:Mathew P. Arens/Chief Executive Officer
    Date:05/15/2026
    Exhibit Information

    Exhibit A: Joint Filing Agreement

    Get the next $TLSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLSI

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    More analyst ratings

    $TLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Marshak Richard sold $1,450 worth of shares (543 units at $2.67), decreasing direct ownership by 0.43% to 125,101 units (SEC Form 4) to cover withholding tax

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    5/19/26 4:08:09 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Director Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    5/18/26 4:42:42 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Director Stansky Michael P bought $1,525,000 worth of shares (610,000 units at $2.50), increasing direct ownership by 49% to 1,240,722 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    5/18/26 4:42:35 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

    Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader market penetration Published landmark, real-world PEDD® Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance despite greater baseline clinical complexity Presented new clinical and preclinical PEDD data across multiple oncology and embolization applications at the 2026 Society of Interventional Radiology Annual Scientific Meeting Strengthened balance sheet with $46 million equity raise; cash balance of $

    5/12/26 4:01:00 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

    Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance despite greater baseline clinical complexity TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery (PEDD®) technology used in t

    5/12/26 8:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients with primary or metastatic liver tumors. The PREDICTT trial is an investigator-led single-arm, prospective, interventional study designed to evaluate how PEDD impacts tumor targeting and radiation dose distribution. Investigators at The

    5/4/26 5:24:00 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on TriSalus Life Sciences

    Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

    2/13/25 8:48:50 AM ET
    $TLSI
    Medical Specialities
    Health Care

    Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

    Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

    12/17/24 8:31:30 AM ET
    $TLSI
    Medical Specialities
    Health Care

    ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

    ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

    11/11/24 7:48:55 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    5/18/26 4:42:42 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Director Stansky Michael P bought $1,525,000 worth of shares (610,000 units at $2.50), increasing direct ownership by 49% to 1,240,722 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    5/18/26 4:42:35 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Chief Financial Officer Patience David bought $17,253 worth of shares (7,100 units at $2.43), increasing direct ownership by 3% to 275,757 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    5/18/26 4:42:24 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun "JJ" Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board expressed their sincere appreciation for Dr. Desai's service and contributions during his tenure. Concurrently, TriSalus announced that Michael P. Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026

    2/9/26 9:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (University Radiology Group, Rutgers Robert Wood Johnson University Hospital), who will join company management to discuss the unmet need and current treatment landscape for uterine fibroids. To register, click here. The event will provide an over

    11/10/25 8:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

    David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance, to serve as acting CFO during transition period TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effec

    5/30/25 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Financials

    Live finance-specific insights

    View All

    TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call

    Conference Call and Webcast Scheduled for Tuesday, May 12, 2026 at 4:30 PM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended March 31, 2026. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the call,

    4/28/26 4:05:00 PM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

    Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance Set initial 2026 revenue guidance of approximately $60-$62 million TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and full-year

    1/12/26 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

    TriSalus Reports $11.6 million in Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth Investigator Published Data Show TriNav Enables Safe, Effective Thyroid Embolization Alternative to Surgery Reaffirmed revenue guidance of at least 50% growth due to continued commercial momentum Hosting Conference Call and Webcast today at 4:30pm ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and pr

    11/13/25 4:01:00 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    12/4/24 4:00:06 PM ET
    $TLSI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    10/21/24 8:25:05 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.

    SCHEDULE 13G/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    5/20/26 4:10:26 PM ET
    $TLSI
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by TriSalus Life Sciences Inc.

    SCHEDULE 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    5/15/26 4:44:22 PM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    5/14/26 4:03:27 PM ET
    $TLSI
    Medical Specialities
    Health Care